Compare Intuitive Surgical, Inc. (ISRG) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intuitive Surgical, Inc. vs Mesoblast Limited — how do they compare? Intuitive Surgical, Inc. trades at $402.8 (market cap $141.75B), while Mesoblast Limited trades at $16.86 (market cap $2.21B). The key difference: Intuitive Surgical, Inc. is far larger — about 64.1× Mesoblast Limited's market cap, and Mesoblast Limited is trading nearer its 52-week high, Intuitive Surgical, Inc. nearer its low. Which is the better fit depends on your goals.
| ISRG | MESO | |
|---|---|---|
Market Cap | $141.75B | $2.21B |
Sector | Health | Technology |
52-Week High | $592.85 | $20.96 |
52-Week Low | $332.02 | $12.88 |
Enterprise Value | $136.53B | $2.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intuitive Surgical (ISRG) trades at $403.95, up 2.69% on the day, reflecting strong momentum. The stock exhibits bullish technical signals with support at $398 and resistance at $403. Fundamentally, revenue grew to $10.06B in 2025 with a net income margin of 28.45%, though valuation ratios like a P/E of 46.01 suggest premium pricing. Recent quarters show consistent earnings beats, with Q2 2026 EPS of $2.80 exceeding expectations. News highlights analyst upgrades and robust adoption of the da Vinci 5 system.
Outlook remains positive driven by innovation and market expansion, but high valuation and competitive pressures pose risks. The consensus price target of $518.10 implies significant upside, supported by 68% buy ratings from analysts. Key risks include reliance on U.S. procedure growth and rising competition from Medtronic and Johnson & Johnson. Long-term growth prospects appear solid if execution continues.
MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.
The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
